Localization of human tumour xenografts after i.v. administration of radiolabelled monoclonal antibodies

Abstract

A mouse monoclonal antibody (LICR-LON/HT13) has been developed to a cell-surface antigen carried on a human germ-cell tumour xenograft (HX39). After radioiodination, the antibody localized in vivo preferentially in xenografted tumours as opposed to normal mouse tissue, whereas tumor uptake did not occur with normal mouse IgG or nonspecific monoclonal IgG. This selective localization could be abolished by simultaneous injection of an excess of the unlabelled LICR-LON/HT13. The kinetics of and factors influencing localization have been examined. Tumour weight was important in that the smaller the tumour the better the localization. LICR-LON/HT13 was found to localize also in other xenografted germ-cell tumours, but not in non-germ-cell tumour xenografts. Thus monoclonal antibodies are capable of selective in vivo localization of human tumours in an animal model, and their clinical value should now be assessed.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Moshakis, V., McIlhinney, R., Raghavan, D. et al. Localization of human tumour xenografts after i.v. administration of radiolabelled monoclonal antibodies. Br J Cancer 44, 91–99 (1981). https://doi.org/10.1038/bjc.1981.153

Download citation

Further reading